Qiagen NV (QGEN) Stock AnalysisQGENStock AnalysisQiagen NV

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight. It operates in the Healthcare sector.

Qiagen NV (QGEN) is currently priced at $43.11, which is close to the analyst price target range of $40 to $48. The forward P/E ratio of 13.64 suggests it may be undervalued compared to its earnings potential. However, the RSI at 48.15 indicates that the stock is neither overbought nor oversold, suggesting caution. The main risk is the recent insider selling trend, which has increased by 286.76% over the last quarter, indicating potential lack of confidence among insiders.

10 analysts cover QGEN: 3 rate it Buy, 7 Hold and 0 Sell. The average price target is 50.57.